Insulin-like growth factor-1 as predictive factor of difficult laryngoscopy in patients with GH-producing pituitary adenoma: A pilot study

2021 ◽  
Vol 94 ◽  
pp. 54-58
Author(s):  
Carmine Iacovazzo ◽  
Clemmaria de Bonis ◽  
Rosario Sara ◽  
Annachiara Marra ◽  
Pasquale Buonanno ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Pilot Study ◽  
Growth Factor ◽  
Predictive Factor ◽  
Difficult Laryngoscopy ◽  
Insulin Like Growth Factor

Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus

2020 ◽  
pp. 1098612X2093321
Author(s):  
Christopher J Scudder ◽  
Katarina Hazuchova ◽  
Ruth Gostelow ◽  
David B Church ◽  
Yaiza Forcada ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Diabetes Mellitus ◽  
Pilot Study ◽  
Growth Factor ◽  
Insulin Dose ◽  
Diabetic Control ◽  
Insulin Like Growth Factor ◽  
Significant Change ◽  
Improve Patient

Objectives An affordable and effective treatment is needed to manage feline hypersomatotropism. The aim of this study was to assess whether treatment with oral cabergoline for 90 days in cats with hypersomatotropism and diabetes mellitus improved diabetic and insulin-like growth factor 1 (IGF-1) control. Methods This was a prospective cohort non-blinded pilot study enrolling client-owned cats with spontaneously occurring diabetes mellitus and hypersomatotropism. Cats received oral cabergoline (5–10 µg/kg q24h) for 90 consecutive days. Serum IGF-1 and fructosamine concentrations were measured on days 1, 30 and 90. Quality of life was determined using the DIAQoL-pet questionnaire on days 1 and 90. Results Nine cats were enrolled and eight completed the study. There was no significant change in the following: IGF-1 (day 1 median 2001 ng/ml [range 890–2001 ng/ml]; day 30 median 2001 ng/ml [range 929–2001 ng/ml]; day 90 median 1828 ng/ml [range 1035–2001 ng/ml]; χ2(2) = 0.667, P = 0.805); fructosamine (day 1 median 499 µmol/l [range 330–887 µmol/l], day 30 median 551 µmol/l [range 288–722 µmol/l], day 90 median 503 [range 315–851 µmol/l]; χ2(2) = 0.581, P = 0.764); or DIAQoL-pet score (median on day 1 –2.79 (range –4.62 to –0.28], median on day 90 –3.24 [range –4.41 to –0.28]; P = 0.715). There was a significant change of insulin dose (χ2(2) = 8.667, P = 0.008) with cats receiving higher insulin doses at day 90 compared with day 1 (median on day 1 was 0.98 [range 0.63–1.49] and median on day 90 was 1.56 [range 0.49–2.55] units/kg q12h; P = 0.026). Conclusions and relevance Cabergoline did not improve diabetic control or normalise insulin-like growth factor concentration, or improve patient quality of life.

Pilot Study of Elevated Levels of Insulin-Like Growth Factor-Binding Protein-2 as Indicators of Hepatocellular Carcinoma

2003 ◽  
Vol 60 (4) ◽  
pp. 174-180 ◽  
Author(s):  
Michael B. Ranke ◽  
Klaus-Peter Maier ◽  
Roland Schweizer ◽  
Bernd Stadler ◽  
Sabine Schleicher ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Pilot Study ◽  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

DECREASE IN ACROMEGALY-ASSOCIATED THYROID ENLARGEMENT AFTER NORMALIZATION OF IGF-1 LEVELS: A PROSPECTIVE OBSERVATION AND IN VITRO STUDY

2020 ◽  
Vol 26 (4) ◽  
pp. 369-377
Author(s):  
Zhiyong Chen ◽  
Xiaobing Jiang ◽  
Yajuan Feng ◽  
Xiaoju Li ◽  
Dubo Chen ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Pituitary Adenoma ◽  
Growth Factor ◽  
Thyroid Volume ◽  
Healthy Controls ◽  
Insulin Like Growth Factor ◽  
Secretory Function ◽  
Thyroid Cells ◽  
Nonfunctioning Pituitary Adenoma

Objective: Goiter occurs at high frequency in acromegaly patients. Whether normalization of insulin-like growth factor 1 (IGF-1) levels could decrease goiter and thyroid volume remains unclear. Methods: Thyroid hormone levels and ultrasound measurements were assessed in 101 acromegaly patients, compared with 108 patients with nonfunctioning pituitary adenoma (NFPA) and 55 healthy controls. Thirty-four acromegaly patients underwent repeat evaluation 1 year post–transsphenoidal surgery. The effect of IGF-1 on thyroid cell proliferation, cell cycle, and apoptosis was evaluated in vitro. Results: Acromegaly patients showed larger thyroid volume than those with NFPAs (18.32 mL vs. 9.91 mL; P<.001) and healthy controls (18.32 mL vs. 9.63 mL; P<.001). Duration of acromegaly was shown to be independently associated with thyroid volume enlargement (B = 0.259; 95% confidence interval, 0.162 to 0.357) in multivariate analysis. At follow-up, the median thyroid volume decreased from 22.74 to 17.87 mL in the cured group (n = 20; P = .003), but the number of nodular goiters showed no significant change. Serum free thyroxine levels decreased from 13.76 to 10.08 pmol/L in the cured group ( P = .006) but increased from 9.28 to 12.09 pmol/L in the active group ( P = .013). Change in thyroid volume was significantly correlated with IGF-1 level ( r = 0.37; P = .029). In vitro, IGF-1 time- and dose-dependently promoted proliferation and secretory function of thyroid cells by enhancing cell cycle shift from the G1/S to G2/M phase and suppressing apoptosis. Conclusion: Acromegaly-associated thyroid volume increase, but not nodular goiter, could be reversed in cured acromegaly. IGF-1 time- and dose-dependently promoted the proliferation and secretory function of thyroid cells. Abbreviations: CCK-8 = Cell Counting Kit-8; fT3 = free triiodothyronine; fT4 = free thyroxine; GH = growth hormone; IGF-1 = insulin-like growth factor 1; MRI = magnetic resonance imaging; NFPA = nonfunctioning pituitary adenoma; qRT-PCR = quantitative real-time–polymerase chain reaction; TSH = thyroid-stimulating hormone

Is preoperative level of insulin-like growth factor 1 (IGF-1) connected with immunohistochemical phenotype of pituitary adenoma in patients with acromegaly?

2019 ◽  
Vol 55 (2) ◽  
pp. 85-90
Author(s):  
Joanna Toszek ◽  
Marek Pawlikowski ◽  
Maria Janowska ◽  
Ewa Wojtczak ◽  
Karolina Beda-Maluga ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Growth Factor ◽  
Proliferation Index ◽  
Oral Glucose ◽  
Insulin Like Growth Factor ◽  
Biochemical Tests ◽  
Ki 67 ◽  
Α Subunit ◽  
Preoperative Serum

Background: Preoperative biochemical diagnosis of acromegaly is based on the determination of the serum levels of insulin-like growth factor 1 (IGF-1) and growth hormone (GH) in the oral glucose tolerance test. In turn, although assumptions concerning the tumour hormonal phenotype may be made on the basis of biochemical tests, the final determination of the exact adenoma profile is possible only on the basis of postoperative immunohistochemical evaluation. Due to the high importance of both – preoperative determination of the concentration of IGF-1 and postoperative immunohistochemical examination of pituitary tumour, the aim of this study was to compare these parameters. Material and methods: The study group consisted of 21 patients with acromegaly and 15 with clinically nonfunctioning pituitary adenoma (CNFPA). In all the patients IGF-1 and prolactin (PRL) concentrations in serum were measured by enzyme–amplified chemiluminescent immunoassay. The immunohistochemical diagnose of the adenoma was achieved with the primary antibodies against the pituitary hormones, the α-subunit and Ki-67 – proliferation indicator. Results: In patients with acromegaly immunohistochemistry besides monohormonal tumours – “pure” somatotropinoma, also somatoprolactinoma and adenoma plurihormonale have revealed. The mean concentrations of IGF-1 were 702, 1480 and 915 ng/mL respectively in each of these groups. In most cases the proliferation index Ki-67 was less than one. In patients with CNFPA, the IGF-1 levels were mostly in reference values and almost in half of cases the Ki–67 value was above one. Conclusions: There are statistically significant differences between preoperative serum IGF-1 concentrations in the somatoprolactinoma group and other adenoma phenotypes in acromegaly patients. This result may suggest the possible link between additional prolactin component with very high concentration of IGF-1 in patients with acromegaly.

Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin-like growth factor in HIV-infected patients

AIDS ◽  
1998 ◽  
Vol 12 (8) ◽  
pp. 895-904 ◽  
Author(s):  
Bach-Yen Nguyen ◽  
Mario Clerici ◽  
David J. Venzon ◽  
Sergio Bauza ◽  
William J. Murphy ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Pilot Study ◽  
Growth Factor ◽  
Human Growth Hormone ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Insulin Like Growth Factor ◽  
Recombinant Insulin
Sign in / Sign up

Export Citation Format

Share Document